Loading...
Market
How will Novo Nordisk's stock price change by end of 2024 due to Ozempic's Alzheimer's study?
2
Resolution / Starting Odds
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Stock market data from major stock exchanges
Story
Novo Nordisk's Ozempic Linked to Significantly Reduced Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 11:08 AM
Novo Nordisk's diabetes medication, Ozempic, has been linked to a significantly reduced risk of Alzheimer's disease, according to a new observational study. The research highlights the drug's potential effects beyond its primary uses for type 2 diabetes and obesity. This finding adds to the growing body of evidence surrounding Ozempic, which is already popular for its benefits in managing diabetes and assisting with weight loss. The study's results are particularly relevant for patients with type 2 diabetes, who may face an increased risk of developing Alzheimer's disease.
View original story
Similar markets
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Below $200 • 25%
$200 - $250 • 25%
$250 - $300 • 25%
Above $300 • 25%
Stock price increases by 10% or more • 25%
Stock price decreases by 10% or more • 25%
Stock price remains within 10% of current value • 25%
Stock price fluctuates but no clear trend • 25%
Significant increase • 25%
Moderate increase • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 5% • 25%
Change within +/- 5% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%